Outcomes of patients with hepaticojejunostomy strictures undergoing endoscopic and percutaneous treatment

Kevin K Choi, Mark H Bonnichsen, Ken Liu, Saniya Massey, Dominic A Staudenmann, Payal Saxena, Arthur Kaffes.

Affiliations below.

DOI: 10.1055/a-1952-2135

Please cite this article as: Choi K K, Bonnichsen M H, Liu K et al. Outcomes of patients with hepaticojejunostomy strictures undergoing endoscopic and percutaneous treatment. Endoscopy International Open 2022. doi: 10.1055/a-1952-2135

Conflict of Interest: The authors declare that they have no conflict of interest.

Abstract:
Background: Rising hepaticojejunostomy surgeries have led to an increase in benign strictures of the anastomosis. Double balloon enteroscopy assisted ERCP (DBE-ERCP) and percutaneous transhepatic biliary drainage (PTBD) are treatment options however there is lack of long-term outcomes, with no consensus on management. We performed a retrospective study assessing the outcomes of patients referred for endoscopic management of hepaticojejunostomy anastomotic strictures (HJAS). Methods: All consecutive patients at a tertiary institution underwent endoscopic intervention for suspected HJAS between 2009 and 2021 were enrolled. Results: 82 subjects underwent DBE-ERCP for suspected HJAS. Technical success was 77% (63/82). A HJAS was confirmed in 41 patients. Clinical success of DBE-ERCP +/- PTBD was 71% (29/41). DBE-ERCP alone achieved clinical success in 49% (20/41). PTBD was required in 49% (20/41). Dual therapy was required in 22% (9/41). Those with liver transplant had lower technical success compared to other surgeries (72.1% vs 82.1% p=0.29), lower clinical success with DBE-ERCP alone (40% vs 62.5% p=0.16) and required more PTBD (56% vs 37.5% p=0.25). All those with ischemic biliopathy (n=9) required PTBD for clinical success, required more DBE-ERCP (4.4 vs 2.0, p=0.004), more PTBD (4.7 vs 0.3, p<0.0001), longer treatment duration (181.6 vs 99.5 days p=0.12) and had higher recurrence (55.6% vs 30.3% p=0.18) compared to those with HJAS alone. Liver transplant was the leading cause of ischemic biliopathy (89%). The overall adverse event rate was 7%. Conclusion: DBE-ERCP is an effective diagnostic and therapeutic tool in those with altered gastrointestinal anatomy and is associated with low complication rates.

Corresponding Author:
Arthur Kaffes, Royal Prince Alfred Hospital, AW Morrow Gastroenterology and Liver Centre, Camperdown, Australia, arthur@kaffes.com

Affiliations:
Kevin K Choi, Royal Prince Alfred Hospital, AW Morrow Gastroenterology and Liver, Sydney, Australia
Mark H Bonnichsen, Liverpool Hospital, Gastroenterology and Hepatology, Sydney, Australia
Ken Liu, Royal Prince Alfred Hospital, Gastroenterology and Hepatology, Camperdown, Australia
Arthur Kaffes, Royal Prince Alfred Hospital, AW Morrow Gastroenterology and Liver Centre, Camperdown, Australia
Title: Outcomes of patients with hepaticojejunostomy anastomotic strictures undergoing endoscopic and percutaneous treatment

Authors:
Kevin Kyung Ho Choi1,2
Mark Bonnichsen1
Ken Liu1,2
Saniya Massey2
Dominic Staudenmann1
Payal Saxena1,2
Arthur John Kaffes1,2

Affiliations:
1 AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia
2 Sydney Medical School, University of Sydney, Sydney, Australia

Abstract word count: 250
Main body word count: 2989
No. of tables: 3 No. of figures: 5

Corresponding Author:
A/Prof Arthur John Kaffes
AW Morrow Gastroenterology and Liver Centre
Authors’ declaration of personal interests:
All authors have nothing to disclose in relation to this manuscript.

Human/Animal Rights: National Statement on Ethical Conduct in Human Research (2007, updated 2018), the CPMP/ICH Note for Guidance on Good Clinical Practice and consistent with the principles that have their origin in the Declaration of Helsinki. Compliance with these standards provides assurance that the rights, safety, and well-being of trial participants are respected.

Author contributions:
Kevin Kyung Ho Choi – Data acquisition, analysis and interpretation of data and wrote the paper
Mark Bonnichsen – Data acquisition and analyses, assisted in writing aspects of the paper
Ken Liu – Statistical analyses of data
Saniya Massey – Data collection
Dominic Staudenmann - Critical revision of the article
Arthur J Kaffes, Payal Saxena – Study concept and design, interpretation of data, drafting of the article, critical revision of the article

All authors have read and approved the final version.
All authors have contributed to the paper and have not submitted the manuscript, in whole or in part, to other journals.

**Abbreviations:** DBE- Double balloon enteroscopy, HJ- Hepaticojejunostomy ERCP- Endoscopic retrograde cholangiopancreatography
**Background:** Rising hepaticojejunostomy surgeries have led to an increase in benign strictures of the anastomosis. Double balloon enteroscopy assisted ERCP (DBE-ERCP) and percutaneous transhepatic biliary drainage (PTBD) are treatment options however there is lack of long-term outcomes, with no consensus on management. We performed a retrospective study assessing the outcomes of patients referred for endoscopic management of hepaticojejunostomy anastomotic strictures (HJAS).

**Methods:** All consecutive patients at a tertiary institution underwent endoscopic intervention for suspected HJAS between 2009 and 2021 were enrolled.

**Results:** 82 subjects underwent DBE-ERCP for suspected HJAS. Technical success was 77% (63/82). A HJAS was confirmed in 41 patients. Clinical success of DBE-ERCP +/- PTBD was 71% (29/41). DBE-ERCP alone achieved clinical success in 49% (20/41). PTBD was required in 49% (20/41). Dual therapy was required in 22% (9/41). Those with liver transplant had lower technical success compared to other surgeries (72.1% vs 82.1% p=0.29), lower clinical success with DBE-ERCP alone (40% vs 62.5% p=0.16) and required more PTBD (56% vs 37.5% p=0.25). All those with ischemic biliopathy (n=9) required PTBD for clinical success, required more DBE-ERCP (4.4 vs 2.0, p=0.004), more PTBD (4.7 vs 0.3, p<0.0001), longer treatment duration (181.6 vs 99.5 days p=0.12) and had higher recurrence (55.6% vs 30.3% p=0.18) compared to those with HJAS alone. Liver transplant was the leading cause of ischemic biliopathy (89%). The overall adverse event rate was 7%.

**Conclusion:** DBE-ERCP is an effective diagnostic and therapeutic tool in those with altered gastrointestinal anatomy and is associated with low complication rates.
Key words: Hepaticojejunostomy, Anastomotic Stricture, Biliary stricture, Double Balloon Enteroscopy, ERCP
Introduction

Hepaticojejunostomy is a surgical technique used to preserve the anatomical tract after surgical resection of the hepatobiliary system. As the procedure becomes more common, biliary stricture management in patients with hepaticojejunostomy anastomotic stricture (HJAS) presents a complex management issue. HJAS is a long-term complication that is estimated to occur in 3 - 13% of patients developing at a median of 2 - 4 years post procedure and can lead to recurrent cholangitis, jaundice, and stone formation [1,2].

Percutaneous transhepatic cholangiogram guided biliary drainage (PTBD) and surgical intervention has reported high success rates, however these require an external drain reducing patient mobility. It is also associated with adverse events ranging from 11 – 35% including hepatic artery injury, haemorrhage, post-procedure sepsis, liver abscess and pneumothorax [3–6]. Traditional endoscopic retrograde cholangiopancreatography (ERCP) is limited by lack of access to the anastomosis given the length of the afferent limb, with low cannulation success rates of 33%[7].

Double balloon enteroscopy-assisted ERCP (DBE-ERCP) has shown success in visualisation of the bile ducts in those with surgically altered anatomy [8–11]. Recent studies [12–17] have shown good efficacy and safety of this technique as a strategy with clinical success rates reported to be between 50 - 100%. DBE-ERCP presents a reasonable alternative to PTBD to address HJAS but the long-term outcomes and optimal management strategy are not well elucidated. The aim of this retrospective study in a high-volume referral centre was to outline the outcomes of HJAS management.
Methods

Patients

We performed a retrospective single centre study of consecutive patients who underwent DBE-ERCP for management of HJAS between February 2009 and August 2021 at Royal Prince Alfred Hospital, a quaternary referral liver transplant university hospital. Ethics approval was granted via the Sydney Local Health District ethics committee (X19-0423 & 2019/ETH12850). All patients who underwent DBE-ERCP for suspected HJAS aged >18 were included. Patients referred with a suspected HJAS had deranged LFTS (Bilirubin, ALP, GGT at least 1.5x above upper limit of normal in at least 2 markers) and one or more of the following, fever (temperature >37.5), imaging (CT Cholangiogram or MRCP) consistent with a HJAS and abdominal pain. Patients were excluded if there was no hepaticojejunostomy (i.e Roux-en-Y bypass), no definitive diagnosis of a HJAS was made or ischemic biliopathy was present without HJAS.

Endoscopic procedure

DBE-ERCP was carried with the Fujinon therapeutic long double balloon enteroscope (Fujinon Corp., Saitama, Japan) with the following components: EN-450T5/20 video enteroscope (3.2-mm channel, 200-cm working length, and 8.5-mm external diameter), 400 (VP- 402, XL 402) processor and a TS-12140 overtube (140-cm length and 12-mm external diameter), two latex balloons (one each at the distal end of the enteroscope and the overtube), and a PB-10 balloon controller (pressure-controlled pump) with the method described previously [8,12]

Once the hepaticojejunostomy anastomosis was reached, a cannulation catheter (4.5 or 5.5Fr tapered cannula 320cm, Cook Medical, Bloomington, IN, USA) with a 480cm or 600cm
0.35 tracer wire was used to cannulate the bile duct. This was followed by the insertion of a balloon dilatation catheter (4 - 6mm, 6 - 8mm, Boston Scientific, Natick, MA, USA) across the stricture and a dilatation was performed with the size of balloon corresponding to the bile duct width above the anastomosis. The balloon was inflated for 30 - 60s to ensure complete dilatation. Upon endoscopic assessment of successful dilatation of the HJAS and confirmation of adequate contrast material flow into the jejunum, the procedure was determined complete. The benign HJAS was endoscopically treated with a single balloon dilatation alone or in combination with deployment of a single plastic stent (3Fr, 5Fr, 7Fr) depending on the severity of the stricture at the endoscopist’s discretion. All patients received prophylactic intra-procedural antibiotics. All procedures were performed by two experienced by endoscopists (AJK, PS) with more than 10 years of DBE-ERCP experience. If patients were successfully dilated, patients were monitored for symptoms and blood tests in an outpatient clinic between 1 - 6 months for the first year, then yearly thereafter. If stents were placed, repeat DBE-ERCP was performed every 2 - 4 months until resolution of stricture.

PTBD was performed in the interventional radiology department. After achieving biliary access, the HJAS and intra-hepatic strictures (referred to as ischemic biliopathy) were treated with a combination of plastic stents, balloon dilatation and drain up-sizing.

Study definitions

A HJAS was defined endoscopically by a stenosis at the anastomotic site without surrounding irregular mucosa and/or narrowing at the hepaticojejunostomy on cholangiogram with relative upstream dilatation of the bile duct. Ischemic biliopathy was defined as intra-hepatic biliary strictures seen on cholangiogram or imaging (CT or MRI).
Treatment duration was defined from the first attempted DBE-ERCP to the final procedure (DBE-ERCP or PTBD) with stent/drain removal or dilatation. Technical success was defined as reaching the HJ anastomosis. Clinical success was defined as complete resolution of stricture determined by improvement of clinical symptoms and laboratory results at follow up visits (normalisation of cholestatic LFTs or >50% reduction). Treatment failure was defined as patients needing to undergo surgery to resolve cholestasis. Follow-up was defined as time from the day of first procedure to the last follow up date. This was confirmed by electronic medical records or calling the patient if there was no recorded follow-up within the past 6 months. Recurrence was defined as elevated liver enzymes with or without cholangitis, with imaging showing bile duct dilatation leading to intervention.

Adverse events (AEs) were classified in relation to scope insertion or ERCP (early ≤7days or late >7 days) and recorded in accordance with the American Society of Gastrointestinal Lexicon for endoscopic AEs [18].

**Statistical analysis**

Continuous variables were expressed in median (interquartile range [IQR]) or mean (range) as appropriate. Differences between subgroups were analysed using chi square test for categorical parameters and t test and Kruskal-Wallis test or ANOVA for parametric and non-parametric data. Statistical analysis was performed by Statistical Package for Social Science (SPSS version 22.0, Armonk, NY, USA). A result was considered statistically significant if \( P<0.05 \). Kaplan-Meier curves were used to estimate the probability of recurrence.

**Results**
Demographics

A total of 82 patients were referred to our centre with a suspected HJAS. 41 patients were confirmed to have a HJAS, of which 65.9% were male. The mean age was 49 years (range 20 – 80). Liver transplant was the most common cause of hepaticojejunostomy 61% followed by bile duct injury 22%, Whipple’s surgery 7%, Choledochal cyst 5% and recurrent pyogenic cholangitis 5%. The mean follow-up duration was 3.2 years (Table 1).

Interventions

DBE-ERCP alone achieved clinical success in 20 patients, of these 13 patients had stents with or without dilatation and 7 patients had dilatation alone. Dual therapy with DBE-ERCP and PTBD were required in 9 patients. Due to failure with DBE-ERCP, PTBD alone achieved clinical success in 11 patients. Across all patients there was a mean of 3.3 (range 1 – 9) DBE-ERCPs and 2.9 PTBDs (range 0 – 14).

Patient flow and stricture management

A total of 82 subjects were referred for the treatment of a suspected HJAS (Figure 1). Failure to reach the hepaticojejunostomy occurred in 23% (19/82). The hepaticojejunostomy was reached in 77% (63/82) and HJAS was confirmed in 56% (35/63) with DBE-ERCP (Figure 2). An additional 5 cases of HJAS were managed with PTBD after DBE failed (Figure 3), and 1 patient was managed conservatively making a total of 41 patients with HJAS studied. In the 28 cases where the hepaticojejunostomy was reached but did not reveal a HJAS, the pathology found included: patent hepaticojejunostomy with reflux cholangitis 64% (18/28), ischemic biliopathy 14% (4/28), choledocholithiasis 11% (3/28) and suture material 11% (3/28).
Of the 41 cases with confirmed HJAS, DBE-ERCP alone had an overall clinical success rate of 49% (20/41). Overall, PTBD was required in 49% (20/41) of patients and conservative management was pursued in 1 patient. Dual therapy was required in 22% (9/41). Clinical success in those who had DBE-ERCP with or without PTBD was 71% (29/41). There was no treatment failure in those with a confirmed HJAS.

There were two groups of patients identified within our cohort. HJAS alone was present in 32 patients and 9 patients had combined HJAS and ischemic biliopathy strictures. The overall recurrence rate in all those with HJAS was 36.6% (15/41).

Results according to liver transplant or non-liver transplant

Liver transplant (n = 43) vs other surgery (n = 39) in those with suspected HJAS

Those with liver transplants had a lower technical success rate (72.1% vs. 82.1%, P = 0.29), required more PTBD (56% vs. 37.5%, P = 0.25) and had lower clinical success with DBE-ERCP alone (40% vs. 62.5%, P = 0.16) (Table 2). Recurrence rates were similar across both groups in those with confirmed HJAS (39.1% vs. 37.5%, P = 0.40) (Table 3).

Liver transplant group with confirmed HJAS (n = 25)

Out of the 41 patients who had a confirmed HJAS, liver transplant was the most common indication for hepaticojejunostomy comprising of 61% (25/41) of subjects. PTBD was required in 56% (14/25) in those with a liver transplant related hepaticojejunostomy. Furthermore, 88.9% (8/9) of those with combined pathology of HJAS and ischemic biliopathy had a prior liver transplant (Figure 4).
Results according to presence or absence of ischemic biliopathy

**HJAS alone**

In those with a simple HJAS alone without ischemic biliopathy, DBE-ERCP alone achieved clinical success in 69% (20/29) of patients. If the hepaticojejunostomy was reached and endoscopic therapy with DBE-ERCP was successfully performed at time of reaching, clinical success with DBE-ERCP alone was 90.5% (20/22). In those who were initially treated with DBE-ERCP, 7 patients were successfully treated with dilatation alone, 13 required stenting (mean of 2 stents per patients, range 1 - 8) with or without dilatation and 2 required PTBD in this group. There was a mean of 2.1 (range 3 - 7) DBE-ERCPs and 0.1 PTBDs (range 0 - 1) per patient.

**Combined HJAS and ischemic biliopathy**

There were 9 patients with combined HJAS and ischemic biliopathy. DBE-ERCP was initially successful in 7 subjects, whereas 2 went to rescue PTBD as DBE-ERCP therapy was unsuccessful. All 9 patients with ischemic biliopathy required PTBD for clinical success. There was a mean of 4.4 DBE-ERCPs and 4.7 PTBDs per patient.

**HJAS alone (n = 30) vs. combined HJAS and Ischemic biliopathy (n = 9)**

Those with combined HJAS and ischemic biliopathy required more DBE-ERCP (mean 4.4 vs 2.1, P = 0.004), PTBD (4.7 vs 0.1, P < 0.0001) and longer treatment duration (181.6 vs 99.5, P = 0.12). Ischemic biliopathy was seen more commonly in those with liver transplants, 89% vs 53% (P = 0.05). Recurrence rates in those with ischemic biliopathy were higher (55.6% vs...
33.3%, P = 0.23) (Table 2). Kaplan-Meier curves showed an increased cumulative incidence of recurrence (Log rank p = 0.002) in those with HJAS with ischemic biliopathy (Figure 5).

Adverse events

In those with confirmed HJAS who had DBE-ERCP, the overall adverse event rate was 7% (3/41) which led to procedural intervention or resulted in death. There was a perforation which required operative management in the dilatation group whereby the initial surgery was during paediatric years in another country. Explant revealed the hepaticojejunostomy site had not been adequately sutured. There was a single unrelated death secondary to sepsis of a patient with acute rejection of a second liver transplant with ischemic biliary strictures that did not respond to DBE-ERCP and PTBD. Cholangitis developed in 1 patient despite intra-procedural antibiotics, however, was managed conservatively with oral antibiotics as an outpatient.

Discussion

HJAS development is an increasingly common and complex clinical problem [19,20]. PTBD is thought to be the gold standard for biliary drainage when conventional ERCP is unable to reach the biliary anastomosis [21–24]. Recent data has shown that DBE-ERCP is a reasonable alternative to PTBD with clinical success rates reported between 50 – 100% [12,13,15–17].

There is only one small case series of predominantly liver transplant patients from Japan that report technical success of 85%, clinical success rates of DBE-ERCP in combination with
PTBD of 70% and clinical success with DBE-ERCP alone of 55% [14]. Our study reports the use of DBE-ERCP in those with suspected HJAS in a larger Western population showing a technical success rate of 77%. All patients who achieved technical success received a diagnosis and/or therapy. Importantly, DBE-ERCP ruled out HJAS and negated the need for PTBD in a third of the cohort. Thus, DBE-ERCP is a powerful therapeutic and minimally invasive diagnostic tool. DBE-ERCP failed to achieve diagnosis or therapy in 23% and subsequently required PTBD (58%, 11/19), conservative management (32%, 6/19) or surgery (10%, 2/19). This is in keeping with data shown in our previous DBE-ERCP experience that those with re-do Roux-en-Y surgery and liver transplants have failure rates of 54% and 36%, respectively [8] .

DBE-ERCP alone led to clinical success in 49% of all those with confirmed HJAS, and DBE-ERCP and PTBD combined had a clinical success rate of 71%. Clinical success rates are reported between 55 and 100% however are all retrospective, have heterogenous populations and are from a predominantly south-east Asian cohort [12—17]. The highest clinical success rate of 95.7% reported by a large retrospective study in Japan of 139 subjects, contained a small liver transplant cohort of 7% compared to our 61%. Additionally, a more manoeuvrable short-DBE was utilized, and the cohort consisted of a South-East Asian population [15]. Thus, our lower clinical success rates are explained by our predominant liver transplant cohort, a Western population, and the technically challenging use of a long DBE system.

From our experience, the liver transplant population is more challenging to treat. There was a trend towards lower technical success and lower clinical success in those with liver transplants compared to other surgeries (72.1% vs. 82.1% P = 0.29 and 56% vs. 37.5% P = 0.25, respectively). There was no difference in recurrence rates between the two groups (P
This is perhaps due to the nature of orthotopic liver transplants causing adhesions, acute angulations and fixed looping leading to a challenging procedure. Although P-values did not reach statistical significance, we attribute this to small case numbers. Furthermore, liver transplant is a key risk factor in developing ischemic biliopathy. Out of the 9 patients with combined HJAS and ischemic biliopathy, 89% were due to a liver transplant. All those with confirmed combined HJAS and ischemic biliopathy required PTBD for clinical success due to difficulty in treating strictures in peripheral ducts. Our results also demonstrated that those with combined HJAS and ischemic biliopathy required more DBE-ERCP, more PTBD, longer treatment duration and had higher recurrence rates. Thus, those with combined HJAS and ischemic biliopathy should be directed to PTBD for the management of their HJAS and intra-hepatic strictures. During PTBD, if decision for stent placement is made, only biodegradable stents should be deployed due to poor accessibility of the hepaticojejunostomy anastomotic site with balloon-assisted enteroscopy.

The major complication rate in the cohort was 7%. This is in keeping with a meta-analysis showing that double balloon enteroscopy assisted ERCP which demonstrated complication rate was around 6.27% [25]. PTBD has the advantage of ease of access for subsequent procedures if required however the requirement for drain care has negative impacts on patient mobility, quality of life and has been associated with poorer outcomes compared to endoscopic biliary drainage [4,14]. It was also seen from a retrospective analysis that nearly a quarter of patients who had PTBD had a drain in situ at 4 years [26]. Moreover, PTBD is associated with a high rate of adverse events of 30% with recurrence rates at 1 year of up to 48 - 60% [27–29]. One study showed that clinical success and adverse event rates were comparable between both enteroscopy assisted ERCP and PTBD groups [16].
EUS guided biliary drainage has been gaining momentum and shows comparable clinical efficacy when compared standard ERCP [30]. A multi-centre retrospective trial of 98 patients comparing EUS-guided biliary drainage and enteroscopy-assisted ERCP revealed higher clinical success rates (88% vs 59.1%, P = 0.03) using EUS guided methods, however accompanied a significant higher adverse event rate of 20% vs 4% (P = 0.01) [31]. There is scant high-quality data on EUS guided biliary drainage in surgically altered anatomy, especially in liver transplant patients. Stents placed via EUS guided biliary drainage have the disadvantage of being permanent in the event of stent blockage or dysfunction limiting future therapeutic options.

The main strength of this study is that it shows real world outcomes in a high-volume liver transplant centre with experienced interventional endoscopists. Limitations of the study related to its retrospective nature and susceptibility to selection bias. The most notable is that patients were subject to treatment bias as treatment was individualized to endoscopic and radiographic findings as well as the expert endoscopists discretion. Simpler strictures may have been subject to dilatation alone and more complex treatments to those with combined HJAS and ischemic biliopathy. In addition, our centre is a primary DBE-ERCP referral centre for a large population in Australia. Thus, our results and decision making may not be generalizable to other smaller centres without balloon-assisted enteroscopy services.

In conclusion, technical success and clinical success rates reached over 70% in our study showing DBE-ERCP in combination with PTBD is an effective diagnostic and therapeutic tool in those with altered gastrointestinal anatomy with low complication rates. Ischemic biliopathy should be assessed radiologically (CT or MRI) in liver transplant patients with
suspected HJAS and referred for primary PTBD therapy if found. Those with severe HJAS requiring stents should have biodegradable stents placed during PTBD as reaching the hepaticojejunostomy may not be feasible. EUS guided biliary drainage for HJAS should be considered in expert centres and requires further studies to assess its safety and efficacy in liver transplant subjects with HJAS. Future research should focus on prospective trials on the comparison of liver transplant outcomes with other surgical outcomes on the formation of hepaticojejunostomies. Additionally, studies using biodegradable stents should be pursued in HJAS to assess safety and efficacy.


31. Khashab M, el Zein M, Sharzehi K et al. EUS-guided biliary drainage or enteroscopy-assisted ERCP in patients with surgical anatomy and biliary obstruction: an international comparative study. Endosc Int Open 2016; 4: E1322- E1327

Figure Legend

Figure 1. Hepaticojejunostomy stricture study flow diagram
DBE-ERCP – Double balloon enteroscopy assisted endoscopic retrograde cholangiopancreatography, HJAS – Hepaticojejunostomy anastomotic stricture, IB – Ischemic biliopathy, PTBD – Percutaneous transhepatic biliary drainage

Figure 2. Endoscopic and radiographic images of endoscopic treatment of Patient A during a single session. a) Endoscopic view of the hepaticojejunostomy anastomotic stricture (HJAS). b) Double balloon enteroscope assisted cholangiogram showing dilated intra-hepatic ducts with contrast hold up. c) Wire guided cannulation through HJAS. d) DBE-ERCP balloon dilatation across HJAS with visible waisting. e) Successful drainage of contrast post-dilatation.

Figure 3. Endoscopic and radiographic images of Patient B requiring percutaneous transhepatic biliary drainage (PTBD) a) Endoscopic view of hepaticojejunostomy anastomotic stricture (red arrow) with adjacent remnant suture string covered with debris/sludge (blue arrow). The wire could not be advanced through the HJAS endoscopically and the patient was referred for PTBD. b) Percutaneous transhepatic cholangiogram (PTC) showing dilated intra-hepatic ducts with no flow of contrast into the small bowel. c) Wire traversed through HJAS into small bowel shown on PTC. d) Percutaneous transhepatic balloon dilatation with waisting visible across the HJAS. e) Successful biliary drainage with contrast flowing through the hepaticojejunostomy into the small bowel.

Figure 4. A Cholangiogram during DBE-ERCP showing a HJAS (red arrow) in combination with ischemic biliopathy (blue arrow)

Figure 5. Kaplan-Meier curves comparing the recurrence rate in those with HJAS alone compared against HJAS with ischemic biliopathy
<table>
<thead>
<tr>
<th>Table 1 DBE-ERCP +/- PTBD Patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total number of patients</strong></td>
</tr>
<tr>
<td><strong>Sex</strong></td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td><strong>Mean Age (Range)</strong></td>
</tr>
<tr>
<td><strong>Indication for hepaticojejunostomy surgery</strong></td>
</tr>
<tr>
<td>Liver transplant</td>
</tr>
<tr>
<td>Bile duct injury</td>
</tr>
<tr>
<td>Whipple’s procedure</td>
</tr>
<tr>
<td>Choledochal cyst</td>
</tr>
<tr>
<td>Recurrent pyogenic cholangitis</td>
</tr>
<tr>
<td><strong>Mean time (range) to stricture formation (years)</strong></td>
</tr>
<tr>
<td><strong>Mean number of DBE-ERCP (range)</strong></td>
</tr>
<tr>
<td><strong>Mean number of PTBD (range)</strong></td>
</tr>
<tr>
<td><strong>Mean follow-up in years (range)</strong></td>
</tr>
<tr>
<td><strong>Complications related to DBE-ERCP</strong></td>
</tr>
</tbody>
</table>

DBE-ERCP – Double balloon enteroscopy assisted endoscopic retrograde cholangiopancreatography, HJAS – Hepaticojejunostomy anastomotic stricture, PTBD – Percutaneous transhepatic biliary drainage
Table 2 Technical success, need for PTBD and ability to achieve clinical success with DBE-ERCP in those with liver transplant vs. other surgeries

<table>
<thead>
<tr>
<th></th>
<th>Liver transplant</th>
<th>Other Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Technical success (all patients referred for suspected HJAS)</td>
<td>72.1% (31/43)</td>
<td>82.1% (32/39)</td>
</tr>
<tr>
<td></td>
<td>P = 0.29</td>
<td></td>
</tr>
<tr>
<td>Need for PTBD in confirmed HJAS with or without ischemic biliopathy</td>
<td>56% (14/25)</td>
<td>37.5% (6/16)</td>
</tr>
<tr>
<td></td>
<td>P = 0.25</td>
<td></td>
</tr>
<tr>
<td>Clinical success with DBE-ERCP alone in confirmed HJAS with or without ischemic biliopathy</td>
<td>40% (10/25)</td>
<td>62.5% (10/16)</td>
</tr>
<tr>
<td></td>
<td>P = 0.16</td>
<td></td>
</tr>
</tbody>
</table>

DBE-ERCP – Double balloon enteroscopy assisted endoscopic retrograde cholangiopancreatography, HJAS – Hepaticojejunostomy anastomotic stricture, PTBD – Percutaneous transhepatic biliary drainage
Table 3 HJAS recurrence by liver transplant vs. other surgery and presence/absence of ischemic biliopathy

<table>
<thead>
<tr>
<th></th>
<th>Liver Transplant</th>
<th>Other surgery</th>
<th>HJAS alone</th>
<th>Combined HJAS and ischemic biliopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>23*</td>
<td>16*</td>
<td>30*</td>
<td>9</td>
</tr>
<tr>
<td>Recurrence n</td>
<td>9</td>
<td>6</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Percentage</td>
<td>39.1% vs 37.5%</td>
<td></td>
<td>33.3%</td>
<td>55.6%</td>
</tr>
<tr>
<td></td>
<td>P = 0.40</td>
<td></td>
<td>P = 0.23</td>
<td></td>
</tr>
</tbody>
</table>

Overall recurrence rate: 38.4%

*1 subject who had a perforation and 1 patient who had perforation were excluded from the recurrence analysis

HJAS – Hepaticojejunostomy anastomotic stricture
Patients referred for a suspected HJAS  
\( n = 82 \)

- Reached hepaticojejunostomy  
  \( n = 63 \)
  - No HJAS  
    \( n = 28 \)
    - HJAS confirmed  
      \( n = 35 \)  
        - HJAS with IB  
          \( n = 7 \)  
        - HJAS alone  
          \( n = 22 \)  
          - Dual therapy (DBE-ERCP & PTBD)  
            \( n = 20 \)
          - DBE-ERCP  
            \( n = 7 \)
    - HJAS alone  
      \( n = 6 \)  
      - Dual therapy (DBE-ERCP & PTBD)  
        \( n = 2 \)
      - PTBD  
        \( n = 5 \)  
        - HJAS alone  
          \( n = 3 \)
        - HJAS with IB  
          \( n = 2 \)
  - Surgery  
    \( n = 2 \)
  - PTBD  
    \( n = 11 \)
  - Conservative management  
    \( n = 6 \)
- Did not reach hepaticojejunostomy  
  \( n = 19 \)
  - IB without HJAS  
    \( n = 5 \)